UBS Turns More Bullish on CVS Health (CVS) with $96 Price Target

Core Insights - CVS Health Corporation is recognized as one of the 13 most undervalued dividend stocks according to Wall Street analysts [1] - UBS has increased its price target for CVS from $79 to $96, maintaining a Buy rating on the stock [2] Financial Performance - In the third-quarter 2025 earnings report, CVS reported revenues of $102.8 billion, reflecting a 7.8% increase year-over-year [3] - The company generated $7.2 billion in cash flow from operations year-to-date and updated its full-year guidance to a range of $7.5 billion to $8.0 billion, an increase from the previous estimate of at least $7.5 billion [3] Dividend Information - CVS has a strong history of consistent dividend payments, having distributed regular dividends since 1997 [4] - The company currently offers a quarterly dividend of $0.665 per share, resulting in a dividend yield of 3.30% as of October 29 [4]